Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Uveal Melanoma 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Neurofibromatosis 1 1Neoplasm Metastasis 1Leukemia, Myelomonocytic, Juvenile 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 5lenvatinib 3cabozantinib 3Sunitinib 3Iodine-131 3trametinib 2Fluorodeoxyglucose F18 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2vandetanib 1tremelimumab 1tanespimycin 1romidepsin 1pembrolizumab 1omipalisib 1durvalumab 1dabrafenib 1cediranib 1aflibercept 1Vorinostat 1Thyrotropin Alfa 1Specimen Handling 1Sorafenib 1Pharmacogenomic Testing 1Nivolumab 1Lenalidomide 1Ipilimumab 1Iodine-124 1Gefitinib 1Decitabine 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma, Follicular × omipalisib × Clear all
NCT02152995 2026-04-13

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
34 enrolled 18 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡